-
Surgery PD-1: After O drug, K drug, I drug, the first indication of T drug was also withdrawn
Time of Update: 2021-03-22
▲TG-Bio has joined hands with more than 600 industry colleagues to open in April ▲Recently (March 8, 2021), Roche announced the withdrawal of its PD-L1 antibody Tecentriq from the United States for the second-line treatment of this indication for metastatic urothelial cancer Roche said that this decision was made after consultation with the FDA.
-
[2021 ASCO-GU] Multi-swords and Combinations | Combination Therapy: A powerful tool for the treatment of prostate cancer?
Time of Update: 2021-03-22
*Only for medical professionals to read for reference. From February 11 to 13, 2021, the American Society of Clinical Oncology Symposium on Urogenital Cancer (ASCO-GU 2021) was successfully held on
-
2021 ASCO-GU: Future | Advances in precision diagnosis and treatment of prostate cancer
Time of Update: 2021-03-22
At present, the use of next-generation sequencing (NGS) technology to detect circulating tumor cells (CTC) in the plasma of patients with metastatic castration-resistant prostate cancer (mCRPC) is an important non-invasive genetic testing method.
-
Quick five tests, easy to get the differential diagnosis of overactive bladder
Time of Update: 2021-03-22
In addition, according to the 2019 guidelines of the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), the symptoms of overactive bladder have four components: urgency, frequent urination, nocturia, and urgency.
According to the 2019 AUA/SUFU guidelines, urge incontinence, nocturia, and frequent urination are common symptoms of overactive bladder.
